Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
A new treatment for osteoarthritis that combines cells from the patient in vitro prior to intra-articular injection has demonstrated beneficial effects on arthritic joints in a compassionate use study.
In a retrospective study, risk–benefit analyses suggest that primary prophylaxis against Pneumocystis jirovecii pneumonia is beneficial in patients receiving rituximab and high-dose glucocorticoids.
In a retrospective study, biologic DMARD therapy was associated with faster control of immune checkpoint inhibitor-associated arthritis but also with a shorter time to cancer progression, compared with methotrexate therapy.
Clinical and molecular analysis of autoantibodies against the endonuclease DNase1L3 in patients with systemic lupus erythematosus led to the identification of a subset of pathogenetic antibodies that are cross-reactive with double-stranded DNA.
In screening for post-translational modifications associated with ankylosing spondylitis, researchers have identified a microbiome-metabolite-mediated modification that can lead to neoantigen generation and subsequent autoimmunity.
Characterization of a new mouse model highlights allogeneic bone marrow transplantation and granulocyte colony-stimulating factor neutralization as potential avenues for the treatment of APLAID.
New findings suggest that inhibition of macrophage fumarate hydratase leads to the release of mitochondrial RNA, which in turn mediates type I interferon production.
Following a fracture, γδ T cell expansion in the bone induces the expansion and migration of T helper 17 cells from the gut to the bone to help mediate fracture healing.
Anti-citrullinated protein antibodies precede the development of rheumatoid arthritis, but new results indicate that these antibodies are not necessarily pathogenic, and some might even protect against arthritis.
A comprehensive analysis has identified chromatin looping as the mechanism that underlies the association of a pleiotropic genetic variant with several autoimmune diseases.
Autoimmunity-associated recognition by IL-17A-expressing γδ T cells of high-mannose glycans expressed on kidney cells in patients with lupus nephritis can be mitigated in a mouse lupus model by dietary supplementation with N-acetylglucosamine.
The results of the two BRAVE phase III trials of baricitinib in the treatment of systemic lupus erythematosus were inconclusive, meaning that this clinical trial programme has now been terminated.
In a large cohort of patients with psoriasis, treatment with biologic DMARDs targeting the IL-23 pathway was associated with a reduced risk of developing inflammatory arthritis as compared with anti-TNF treatment.
Protein phosphatase magnesium-dependent 1A is a negative modulator of transforming growth factor β signalling and a potential new therapeutic target in osteoarthritis.
Results indicate that prophylactic use of co-trimoxazole can reduce infection-related mortality in patients with new-onset anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis.
Expression of the Na+-K+-ATPase transmembrane ion transporter is upregulated in kidney-infiltrating B cells in lupus-prone mice and is a potential target for reducing renal B cell survival in patients with lupus nephritis.
A newly developed nanobody that simultaneously targets TNF and IL-6 has greater efficacy than individual targeting in rheumatoid arthritis disease-relevant preclinical models.
Neutrophil extracellular trap proteins trigger an accelerated form of osteoclastogenesis that is enhanced by the presence of carbamylated proteins and is linked to bone erosion.
